List of Excipients in Branded Drug METHAZOLAMIDE

« Back to Dashboard

Generic Drugs Containing METHAZOLAMIDE

Company	Ingredient	NDC	Excipient
Padagis US LLC	methazolamide	0574-0790	CELLULOSE, MICROCRYSTALLINE
Padagis US LLC	methazolamide	0574-0790	CROSCARMELLOSE SODIUM
Padagis US LLC	methazolamide	0574-0790	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Padagis US LLC	methazolamide	0574-0790	MAGNESIUM STEARATE
Padagis US LLC	methazolamide	0574-0790	SILICON DIOXIDE
Sandoz Inc	methazolamide	0781-1072	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	methazolamide	0781-1072	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in METHAZOLAMIDE?

# Of NDCs	Excipient
4	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
13	CELLULOSE, MICROCRYSTALLINE
13	CROSCARMELLOSE SODIUM
16	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
9	GLYCERYL DIBEHENATE
2	HYPROMELLOSE 2910
2	LACTOSE MONOHYDRATE

Methazolamide Excipient Strategy, Formulation Opportunities, and Commercial Outlook

Last updated: October 13, 2026

Methazolamide is an established oral carbonic anhydrase inhibitor used primarily to reduce intraocular pressure in glaucoma. Its commercial opportunity is limited by generic competition, low market growth, and the absence of obvious composition-of-matter exclusivity. The strongest formulation opportunities are likely to involve tablet robustness, swallowability, dose flexibility, excipient substitution, and differentiated packaging rather than a new active-ingredient product.

Methazolamide is marketed in 25 mg and 50 mg oral tablet strengths in the United States. It is related pharmacologically to acetazolamide but has different physicochemical and dosing characteristics. Its commercial formulation strategy should focus on reliable low-dose manufacturing, tolerability, regulatory simplicity, and supply-chain resilience.

What is methazolamide and how is it administered?

Methazolamide is a sulfonamide carbonic anhydrase inhibitor. It reduces aqueous humor production and lowers intraocular pressure. The U.S. labeling for methazolamide identifies oral tablets as the dosage form and lists treatment of glaucoma among its indications.[1]

Attribute	Methazolamide
Active ingredient	Methazolamide
Pharmacologic class	Carbonic anhydrase inhibitor
Primary use	Reduction of elevated intraocular pressure in glaucoma
Common dosage forms	Immediate-release oral tablets
Common strengths	25 mg and 50 mg
Administration	Oral
Regulatory pathway	Small-molecule drug
Biosimilar exposure	None
Main competitive risk	Generic substitution and low-cost supply
Key formulation challenge	Consistent tablet performance at a low drug load

Methazolamide is not a biologic, injectable product, or long-acting delivery system. Biosimilar risk is therefore irrelevant. The relevant competitive threats are generic tablets, authorized-generic supply, therapeutic substitution with acetazolamide, and potential compounded products.

What excipients are used in methazolamide tablets?

The precise excipient composition depends on the manufacturer and product label. U.S. drug labels and DailyMed records should be reviewed by National Drug Code because inactive ingredients can differ between manufacturers and strengths.[1,2]

Typical excipient categories for an immediate-release methazolamide tablet may include:

Excipient function	Potential materials	Formulation purpose
Diluent	Lactose, microcrystalline cellulose, calcium phosphate	Provides tablet mass and improves content uniformity
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup after administration
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Improves appearance, handling, identification, and swallowability
Sweetener or flavor	Product-specific	Relevant mainly to orally disintegrating or chewable formats

A manufacturer should not assume that an excipient listed for one methazolamide product applies to all strengths or suppliers. Formulation changes can affect dissolution, stability, tablet hardness, impurity formation, and bioequivalence.

Which excipients create the greatest regulatory risk?

The highest practical risks are usually associated with:

1. Lactose, where a target market requires lactose-free labeling or where the patient population has sensitivity concerns.
2. Colorants, where patient preference, regional restrictions, or supply continuity are relevant.
3. Sodium-containing excipients, where sodium disclosure may affect positioning for patients with dietary restrictions.
4. Polyols and sugar alcohols in alternative dosage forms, because gastrointestinal tolerability can become a labeling issue.
5. Novel functional excipients, which may trigger additional regulatory scrutiny if the excipient lacks established use at the proposed exposure.

For a conventional generic tablet, an excipient system composed of established compendial materials is generally more commercially efficient than a novel excipient strategy. The regulatory value of a novel excipient is low unless it solves a specific problem such as poor dissolution, unacceptable tablet size, taste, or stability.

How should an excipient platform be designed for methazolamide?

A practical platform should use a direct-compression or dry-granulation architecture unless development data show that wet granulation is needed. Methazolamide has a relatively low dose compared with total tablet weight, so content uniformity and powder segregation require early evaluation.

Immediate-release tablet strategy

The baseline formulation should target:

• Rapid and reproducible disintegration.
• Dissolution performance that is robust across manufacturing sites.
• Adequate hardness without excessive compression force.
• Low friability.
• Stable assay and impurity profile.
• Tablet dimensions suitable for chronic use.
• A scalable process compatible with multiple suppliers.

Microcrystalline cellulose, a suitable disintegrant, a flow aid, and a low-level lubricant can provide a conventional starting platform. The final selection should be based on powder flow, blend uniformity, compaction behavior, dissolution, and stability rather than excipient novelty.

Film-coated tablet strategy

A film coat can create modest commercial differentiation. It can:

• Reduce powdering and improve handling.
• Improve swallowability.
• Permit strength-specific color coding.
• Reduce exposure to light or moisture if the coating and packaging are designed appropriately.
• Support a more consistent brand presentation.

The coating should not materially delay immediate release unless delayed release is an explicit development objective. A color-free or low-color version may create a procurement advantage in markets with tighter excipient restrictions.

Orally disintegrating and chewable formats

An orally disintegrating tablet could address patients with swallowing difficulty, but the commercial case is uncertain. Methazolamide is used in a population that may include older adults, so swallowability has potential value. The main development barriers are taste, dose uniformity, mechanical fragility, moisture sensitivity, and the need to establish acceptable in-use stability.

A chewable formulation would face similar taste and palatability challenges. Carbonic anhydrase inhibitors can have an unpleasant taste profile, making taste masking important. A taste-masked dosage form may require polymer coating, ion-exchange technology, lipid-based masking, or a multiparticulate platform. These approaches increase cost and may weaken the generic-development business case.

What formulation patents could protect a methazolamide product?

A conventional methazolamide tablet is unlikely to obtain meaningful broad patent protection solely from the use of standard excipients. A potentially defensible formulation patent would need to claim a specific technical combination with demonstrated performance.

Potential patent targets include:

Patent target	Potential claim basis	Commercial value
Taste-masked dosage form	Coated particles or polymer matrix with defined dissolution	Moderate if patient acceptance improves
Orally disintegrating tablet	Rapid disintegration with acceptable taste and mechanical strength	Moderate
Low-moisture formulation	Defined excipient system and packaging that improve stability	Moderate if the active is moisture-sensitive
Modified-release system	Controlled plasma exposure or reduced dosing frequency	High, but development risk is substantial
Combination product	Methazolamide with another glaucoma therapy	Potentially high, subject to clinical and regulatory requirements
Device-assisted product	Specialized delivery system	Low for the current oral product profile
Manufacturing process	Defined granulation, compression, or coating process	Usually narrower and easier to design around

Patent strength would depend on unexpected results, claim breadth, enablement, freedom to operate, and whether competing manufacturers can achieve the same performance through different excipients.

A patent claiming only "methazolamide plus a pharmaceutically acceptable excipient" would generally face substantial validity and design-around risk. A stronger claim would tie the composition to measurable outcomes such as dissolution under defined conditions, stability after accelerated storage, tablet tensile strength, disintegration time, or reduced impurity formation.

When does methazolamide lose exclusivity?

Methazolamide is an older small-molecule product. Its original composition-of-matter and early product patents are expected to have expired. Current commercial competition is therefore driven primarily by generic approvals, manufacturing economics, labeling, supply reliability, and market access.

Exclusivity category	Methazolamide position
New chemical entity exclusivity	Expired
Original composition-of-matter protection	Expected expired
Pediatric exclusivity	No current commercial significance identified
Orphan-drug exclusivity	Not a principal protection mechanism
Biosimilar exclusivity	Not applicable
Formulation exclusivity	Depends on any later-approved product-specific claims
Method-of-use protection	Any remaining claims would require product- and jurisdiction-specific review
Generic entry	Available in the established generic market

The exact Orange Book status must be checked against the relevant product and sponsor listing. FDA Orange Book records identify approved drug products, therapeutic-equivalence information, and listed patents where applicable.[3]

What is the Orange Book status of methazolamide?

Methazolamide is an FDA-regulated small-molecule prescription drug, and applicable approved products may appear in the Orange Book or FDA drug databases depending on current marketing status and sponsor activity.[3,4]

The commercial importance of any Orange Book listing is limited unless an active listed patent blocks or delays an abbreviated new drug application. For an older methazolamide tablet, the central diligence questions are:

• Whether a current reference listed drug remains actively marketed.
• Whether the relevant strength has an FDA-designated reference product.
• Whether any active patents are listed.
• Whether an ANDA sponsor has filed a Paragraph IV certification.
• Whether any litigation has triggered a 30-month stay.
• Whether the reference product is discontinued or merely listed as not currently marketed.

A Paragraph IV challenge would be relevant only if an active patent were listed against the reference product. For a legacy immediate-release tablet, the expected risk from active patent litigation is lower than for a recently approved formulation.

Which companies are challenging methazolamide exclusivity?

No specific current Paragraph IV challenger or active federal patent litigation should be presumed without a current FDA and court-docket review. Methazolamide competition is more likely to arise through ordinary ANDA approval, abbreviated labeling, manufacturing transfer, or price competition than through litigation over a recently issued formulation patent.

The likely competitive set includes:

• Generic manufacturers with established ophthalmic and oral carbonic anhydrase inhibitor portfolios.
• Contract manufacturers supplying regional generic companies.
• Manufacturers with low-cost tablet compression and coating capacity.
• Firms seeking niche products with limited competition or intermittent supply.

For this molecule, the absence of active litigation can itself be commercially relevant. It reduces legal barriers to entry but also lowers the ability to preserve premium pricing through patent enforcement.

What generic launch scenarios exist for methazolamide?

Low-cost conventional generic

This is the most straightforward scenario. A manufacturer develops a 25 mg and 50 mg immediate-release tablet using standard excipients and seeks approval through an ANDA. The commercial advantage depends on manufacturing cost, approval timing, supply reliability, and wholesaler access.

Differentiated coated tablet

A film-coated version can improve handling and patient acceptability. The differentiation is modest and may not support a large price premium, but it can help a supplier win institutional contracts.

Lactose-free or excipient-reduced version

A lactose-free formulation can address procurement and patient-labeling preferences. It is more likely to support a niche positioning than broad exclusivity. The formulation must maintain comparable dissolution and tablet manufacturability.

Orally disintegrating tablet

This format could target older adults and patients with dysphagia. The opportunity is constrained by taste masking, moisture protection, and the need to demonstrate bioequivalence or otherwise satisfy FDA requirements.

Combination glaucoma product

Combining methazolamide with another active ingredient could improve adherence but would require a clear clinical and regulatory rationale. Fixed-dose combination development would have higher cost and greater regulatory risk than a conventional generic tablet.

How does methazolamide compare with acetazolamide?

Methazolamide competes directly with acetazolamide as an oral carbonic anhydrase inhibitor, although prescribing decisions depend on indication, dose, tolerability, clinical response, and physician preference.

Factor	Methazolamide	Acetazolamide
Primary relevance	Glaucoma and reduction of intraocular pressure	Glaucoma, altitude sickness, edema, seizures, and other uses
Dosage form exposure	Primarily oral tablets	Tablets, extended-release capsules, and injectable forms depending on market
Formulation opportunity	Swallowability, taste masking, excipient simplification	Broader dosage-form and indication competition
Market breadth	Narrower	Broader
Generic pressure	High	High
Commercial differentiation	Product quality and supply reliability	Dosage form, indication, and formulation breadth

Methazolamide may be attractive for a focused generic portfolio because it has a narrower competitive field than acetazolamide. Its smaller market also limits revenue potential.

What manufacturing and intellectual-property barriers affect methazolamide?

The main barriers are technical and economic rather than patent-based.

Manufacturing barriers

A developer must control:

• Blend uniformity at low active loading.
• Segregation during transfer and compression.
• Tablet capping, sticking, and picking.
• Dissolution variation between strengths.
• Lubrication sensitivity.
• Moisture and temperature effects during storage.
• Supplier changes for critical excipients.
• Packaging performance under humidity exposure.

A formulation that uses common excipients can reduce sourcing risk, but excipient substitutions may still require comparative dissolution, stability, and regulatory assessment.

Intellectual-property barriers

Relevant searches should cover:

• Methazolamide composition patents.
• Salt, polymorph, and crystal-form claims.
• Tablet and coating patents.
• Taste-masking and orally disintegrating formulations.
• Combination glaucoma products.
• Manufacturing-process patents.
• Regulatory exclusivity and Orange Book listings in each target market.

Geographic coverage is material. U.S. patent expiry does not determine freedom to operate in Europe, Japan, Canada, China, or emerging markets. Older active ingredients may have different local formulation patents, supplementary protection certificates, or data-exclusivity rules.

How strong is the commercial opportunity for methazolamide excipients?

The opportunity is moderate for suppliers and niche generic manufacturers, but low for a premium standalone product unless the formulation solves a documented patient or manufacturing problem.

Higher-value opportunities

• Robust, low-cost direct-compression platform.
• Lactose-free or low-excipient tablet.
• Moisture-resistant packaging and formulation.
• Improved swallowability through film coating.
• Taste-masked orally disintegrating product.
• Reliable dual-source excipient strategy.
• Contract development and manufacturing for under-supplied markets.

Lower-value opportunities

• Minor color changes without patient or procurement value.
• Novel excipient claims without measurable performance benefits.
• Premium pricing for a standard uncoated tablet.
• Broad patent claims based only on routine excipient substitution.
• Complex modified release without a clear clinical advantage.

Revenue exposure should be modeled conservatively. Methazolamide is an established generic product with limited exclusivity leverage. A commercial plan should therefore assume price erosion, tender competition, and possible market intermittency. The value is greater when the product is added to an existing glaucoma or specialty-generic portfolio than when launched as a single-product business.

What is the recommended methazolamide excipient strategy?

The preferred development sequence is:

1. Establish a conventional immediate-release tablet using compendial excipients.
2. Develop both lactose-containing and lactose-free prototypes if target-market requirements justify the work.
3. Use film coating for identification, handling, and swallowability.
4. Screen direct compression and dry granulation before adopting more complex processing.
5. Build dissolution and stability robustness into the formulation from the first development batch.
6. Qualify at least two suppliers for critical excipients.
7. Evaluate an orally disintegrating product only after confirming market demand and acceptable taste-masking economics.
8. Protect any differentiated formulation with narrow, data-supported claims tied to measurable performance.
9. Review Orange Book records, FDA labeling, patent databases, and country-specific registers before launch.
10. Treat supply reliability and regulatory execution as the primary commercial differentiators.

Key Takeaways

• Methazolamide is an established oral carbonic anhydrase inhibitor supplied mainly as 25 mg and 50 mg tablets.
• Its original exclusivity is expected to have expired, making generic economics more important than patent duration.
• The strongest baseline formulation is a conventional immediate-release tablet using established excipients.
• Film coating, lactose-free composition, moisture control, and swallowability offer the most practical differentiation.
• Orally disintegrating and taste-masked products have potential but face higher development and regulatory costs.
• Patent value would depend on demonstrated technical performance, not routine excipient substitution.
• Current Paragraph IV challenges, Orange Book patents, and litigation status require product-specific database verification.
• The commercial opportunity is strongest for a manufacturer with existing glaucoma distribution, reliable supply, and low-cost tablet capacity.

FAQs About Methazolamide Formulation and Commercialization

Is methazolamide available as an ophthalmic solution?

Methazolamide is primarily associated with oral tablet therapy. Ophthalmic carbonic anhydrase inhibitor products more commonly use other active ingredients, such as dorzolamide or brinzolamide.

Can methazolamide be developed as an extended-release tablet?

Yes, but the commercial rationale would require evidence of improved adherence, tolerability, or clinical performance. Extended-release development would be more complex than an immediate-release generic and would require robust pharmacokinetic and product-performance justification.

Does methazolamide have biosimilar competition?

No. Methazolamide is a small-molecule drug, so competition occurs through generic drug pathways rather than biosimilar approval pathways.

Which excipient is best for methazolamide tablets?

No single excipient is universally optimal. The preferred system is the one that delivers content uniformity, rapid and reproducible dissolution, mechanical strength, stability, and scalable manufacturing using established materials.

Can a methazolamide excipient change support new patent protection?

Potentially, but a patent would need defensible claims and evidence of an unexpected technical effect. Routine substitution of one conventional diluent, binder, disintegrant, or lubricant is unlikely to provide strong protection by itself.

References

1. DailyMed. (n.d.). Methazolamide tablet: U.S. prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (n.d.). DailyMed drug label database. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/